keyword
MENU ▼
Read by QxMD icon Read
search

HIPEC and Gastric

keyword
https://www.readbyqxmd.com/read/27650694/survival-benefit-of-gastrectomy-for-gastric-cancer-with-peritoneal-carcinomatosis-a-propensity-score-matched-analysis
#1
Xiuwen Geng, Hao Liu, Tian Lin, Yanfeng Hu, Hao Chen, Liying Zhao, Tingyu Mou, Xiaolong Qi, Jiang Yu, Guoxin Li
Peritoneal carcinomatosis (PC) is the most frequent pattern of metastasis in stage IV gastric cancer (GC). The study aims to investigate the efficacy of gastrectomy in GC with PC. Clinicopathological data of 518 stage IV GC patients were retrospectively collected in Nanfang Hospital. Among all cases, 312 GC patients with PC (without other site of metastasis) were eligible. Univariate and multivariate analyses were performed to identify the independent prognostic factors. Propensity score matching analysis was performed to balance the characteristics and treatment-related factors...
October 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27563441/hyperthermic-intraperitoneal-chemotherapy-hipec-and-neoadjuvant-chemotherapy-as-prophylaxis-of-peritoneal-carcinosis-from-advanced-gastric-cancer-effects-on-overall-and-disease-free-survival
#2
Federico Coccolini, Andrea Celotti, Marco Ceresoli, Giulia Montori, Michele Marini, Fausto Catena, Luca Ansaloni
BACKGROUND: The possibility to enlarge criteria for intra-peritoneal chemotherapy (IPC) to all patients at high-risk to develop peritoneal carcinosis (i.e., with serosal invasion) is still discussed. METHODS: Retrospective case-control study. Three-groups: advanced-gastric-cancer (AGC) (pT4) without proven carcinosis: prophylactic group (PG), those with PC: treatment group (TG), AGC (pT3-pT4) operated without hyperthermic intraperitoneal chemotherapy (HIPEC), surgery alone group (SG T3, SG T4)...
August 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/27487625/-management-of-peritoneal-carcinomatosis-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#3
Alexandre Balaphas, Valentina Belfontali, Frédéric Ris, Andreas Lanitis, Raphael P H Meier, Marie-Laure Amram, Arnaud Roth, Olivier Huber, Thierry Berney, Philippe Morel
In 2016, peritoneal carcinomatosis can be considered as a chronic disease that can be treated and sometimes cured. Hyperthermic Intra PEritoneal Chemotherapy (HIPEC) is a procedure developed in the eighties. Combined with CytoReductive (CR) surgery, this protocol underwent a considerable expansion in Washington Cancer Institute. CR combined with HIPEC was demonstrated to be the only curative treatment for PseudoMyxoma Peritonei syndrome (PMP). It is actually approved in the management of peritoneal carcinomatosis of ovarian, colorectal, or peritoneal primitive (mesothelioma) origin but is still studied for gastric cancer...
June 15, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/27446587/a-retrospective-analysis-of-hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-with-peritoneal-metastasis
#4
Meiqin Yuan, Zeng Wang, Guinv Hu, Yunshan Yang, Wangxia Lv, Fangxiao Lu, Haijun Zhong
Peritoneal metastasis (PM) is a poor prognostic factor in patients with gastric cancer. The aim of this study was to evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer with PM by retrospective analysis. A total of 54 gastric cancer patients with positive ascitic fluid cytology were included in this study: 23 patients were treated with systemic chemotherapy combined with HIPEC (HIPEC+ group) and 31 received systemic chemotherapy alone (HIPEC- group)...
August 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27362668/cytoreductive-surgery-combined-with-hyperthermic-intraperitoneal-chemoperfusion-for-the-treatment-of-gastric-cancer-a-single-centre-retrospective-study
#5
Yinuo Tu, Yunhong Tian, Zhiyuan Fang, Qiang Ruan, Hongsheng Tang, Xiangliang Zhang, Yinbing Wu, Yan Ding, Shuzhong Cui
AIM: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemoperfusion (HIPEC) is the treatment regime most likely to achieve prolonged survival in patients with peritoneal carcinomatosis from gastroenteric cancer. To date, few publications have focused on the treatment of patients with gastric cancer alone. Several controversies remain unsolved, including the safety and effectiveness of the CRS-HIPEC combination regime, particularly in cases where HIPEC is used as adjuvant treatment after CRS...
September 2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/27347669/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-the-management-of-gastrointestinal-cancers-with-peritoneal-metastases-progress-toward-a-new-standard-of-care
#6
REVIEW
Paul H Sugarbaker
Peritoneal metastases from gastrointestinal cancer was, in the past, accepted as an inevitable component of the natural history of these diseases. It is a major cause of intestinal obstruction, fistula formation, and bowel perforation as the recurrent malignancy progresses to a terminal condition. Peritoneal metastases may be caused by full thickness penetration of the bowel wall by the primary cancer or by spilled cancer cells released into the peritoneal space by surgical trauma. Two new surgical technologies that have evolved to manage peritoneal metastases are cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)...
July 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27330364/treatment-of-peritoneal-surface-malignancies-with-hyperthermic-intraperitoneal-chemotherapy-current-perspectives
#7
REVIEW
J Spiliotis, E Halkia, E de Bree
Peritoneal carcinomatosis (ptc) represents advanced malignant disease and has generally been associated with a grim prognosis. Peritoneal surface malignancy is often the major source of morbidity and mortality; it is of major concern in cancer management. Although ptc is categorized as metastatic disease, it represents a special disease pattern considered to be a locoregional disease limited to the abdominal cavity. The combination of cytoreductive surgery (crs) and intraoperative hyperthermic intraperitoneal chemotherapy (hipec) has successfully been used as locoregional treatment for selected patients with ptc from gastric, colorectal, and ovarian cancer; with mesothelioma; and with pseudomyxoma peritonei...
June 2016: Current Oncology
https://www.readbyqxmd.com/read/27313067/crs-hipec-prolongs-survival-but-is-not-curative-for-patients-with-peritoneal-carcinomatosis-of-gastric-cancer
#8
T Boerner, A Graichen, T Jeiter, F Zemann, P Renner, L März, Y Soeder, H J Schlitt, P Piso, M H Dahlke
PURPOSE: Peritoneal carcinomatosis (PC) is a dismal feature of gastric cancer that most often is treated by systemic palliative chemotherapy. In this retrospective matched pairs-analysis, we sought to establish whether specific patient subgroups alternatively should be offered a multimodal therapy concept, including cytoreductive surgery (CRS) and intraoperative hyperthermic chemotherapy (HIPEC). METHODS: Clinical outcomes of 38 consecutive patients treated with gastrectomy, CRS and HIPEC for advanced gastric cancer with PC were compared to patients treated by palliative management (with and without gastrectomy) and to patients with advanced gastric cancer with no evidence of PC...
June 16, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27179924/cytoreductive-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-with-lobaplatin-and-docetaxel-to-treat-synchronous-peritoneal-carcinomatosis-from-gastric-cancer-results-from-a-chinese-center
#9
H-T Wu, K-W Peng, Z-H Ji, J-H Sun, Q Zhang, X-J Yang, C-Q Huang, Y Li
BACKGROUND: This work was to evaluate the efficacy and safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with lobaplatin and docetaxel to treat peritoneal carcinomatosis (PC) from gastric cancer (GC). METHODS: A total of 50 consecutive GC PC patients treated by 52 CRS+HIPEC procedures with lobaplatin 50 mg/m(2) and docetaxel 60 mg/m(2) in 6000 mL of normal saline at (43 ± 0.5) °C for 60 min. The primary endpoint was overall survival (OS), and the secondary endpoints were perioperative safety profiles...
July 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27169699/the-role-of-closed-abdomen-hyperthermic-intraperitoneal-chemotherapy-hipec-in-the-palliative-treatment-of-neoplastic-ascites-from-peritoneal-carcinomatosis-report-of-a-single-center-experience
#10
L Orgiano, F Pani, G Astara, C Madeddu, S Marini, A Manca, Giovanni Mantovani
PURPOSE: The purpose of this study was to review the results of a single-center experience in the management of "closed abdomen" hyperthermic intraperitoneal chemotherapy (HIPEC) using a sophisticated technical device (EXIPER®) in the palliative setting of neoplastic ascites from peritoneal carcinomatosis in patients with advanced cancer of different primary sites. PATIENTS AND METHODS: The study was an open, prospective, single-center, non-randomized study conducted at the Department of Medical Oncology 1, University of Cagliari, Italy, from May 2006 to October 2012...
October 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27160355/a-comprehensive-treatment-for-peritoneal-metastases-from-gastric-cancer-with-curative-intent
#11
REVIEW
Y Yonemura, E Canbay, Y Li, F Coccolini, O Glehen, P H Sugarbaker, D Morris, B Moran, S Gonzaletz-Moreno, M Deraco, P Piso, D Elias, D Batlett, H Ishibashi, A Mizumoto, V Verwaal, H Mahtem
Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed...
August 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27110915/what-made-hyperthermic-intraperitoneal-chemotherapy-an-effective-curative-treatment-for-peritoneal-surface-malignancy-a-25-year-experience-with-1-125-procedures
#12
Guillaume Passot, Delphine Vaudoyer, Laurent Villeneuve, Vahan Kepenekian, Annie-Claude Beaujard, Naoual Bakrin, Eddy Cotte, Francois-Noel Gilly, Olivier Glehen
OBJECTIVE: To review our 25-year experience with hyperthermic intra-peritoneal chemotherapy (HIPEC). BACKGROUND: Combining cytoreductive surgery (CRS) and HIPEC as local treatments for peritoneal carcinomatosis (PC) was proposed 25 years ago. METHODS: A prospective database of all patients undergoing HIPEC for PC since 1989 was searched for clinicopathological data, 90-day morbidity and mortality, and survival. RESULTS: Among 1,125 HIPEC procedures, PC origin was colorectal (342; 30%), ovarian (271; 24%), pseudomyxoma peritonei (189; 17%), gastric (127; 11%), malignant mesothelioma (84; 8%), or other (112; 10%)...
June 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27065712/proactive-management-for-gastric-colorectal-and-appendiceal-malignancies-preventing-peritoneal-metastases-with-hyperthermic-intraperitoneal-chemotherapy-hipec
#13
REVIEW
Paolo Sammartino, Daniele Biacchi, Tommaso Cornali, Maurizio Cardi, Fabio Accarpio, Alessio Impagnatiello, Bianca Maria Sollazzo, Angelo Di Giorgio
An integrated treatment strategy using peritonectomy procedures plus hyperthermic intraperitoneal chemotherapy (HIPEC) is now a clinical standard of care in selected patients with peritoneal metastases and primary peritoneal tumors. This comprehensive approach can offer many patients, who hitherto had no hope of cure, a good quality of life and survival despite limited morbidity. The increasingly successful results and chance of interfering in the natural history of disease has prompted research to develop for some clinical conditions a therapeutic strategy designed to prevent malignant peritoneal dissemination before it becomes clinically evident and treat it microscopically (tertiary prevention)...
June 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27065710/the-role-of-hyperthermic-intraperitoneal-chemotherapy-in-gastric-cancer
#14
Ramakrishnan Ayloor Seshadri, Olivier Glehen
Peritoneal metastasis, either synchronous or metachronous, is commonly seen in gastric cancer. It is associated with a poor prognosis, with a median survival of less than one year. The outcomes are not significantly improved by the use of systemic chemotherapy. We review the relevant literature on the role of HIPEC in gastric cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been used in three situations in gastric cancer. Besides its role as a definitive treatment in patients with established peritoneal metastasis (PM), it has been used as a prophylaxis against peritoneal recurrence after curative surgery and also as a palliative treatment in advanced peritoneal metastasis with intractable ascites...
June 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/26941987/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-and-other-less-common-disease-histologies-is-it-time
#15
REVIEW
Paul L Feingold, Mei Li M Kwong, Arvind Sabesan, Rebecca Sorber, Udo Rudloff
Gastric cancer is the fourth most commonly diagnosed cancer worldwide, and once spread to the peritoneum, has a 5-year survival of less than 5%. Recent years have demonstrated advances in the use of cytoreductive surgery (CRS) in combination with heated intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis due to various malignancies. The frequent desmoplastic stroma and poor vascularization impeding drug delivery particularly in the diffuse form of gastric cancer is thought to provide a sound rationale for a regionalized treatment approach in this disease...
February 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/26811651/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-in-gastric-cancer
#16
REVIEW
Ramakrishnan Ayloor Seshadri, Olivier Glehen
Gastric cancer associated peritoneal carcinomatosis (GCPC) has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase the survival in GCPC. Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like aggressive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been investigated for GCPC. HIPEC has been used for three indications in GC- as an adjuvant therapy after a curative surgery, HIPEC has been shown to improve survival and reduce peritoneal recurrences in many randomised trials in Asian countries; as a definitive treatment in established PC, HIPEC along with CRS is the only therapeutic modality that has resulted in long-term survival in select groups of patients; as a palliative treatment in advanced PC with intractable ascites, HIPEC has been shown to control ascites and reduce the need for frequent paracentesis...
January 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/26753751/patients-with-peritoneal-carcinomatosis-from-gastric-cancer-treated-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-is-cure-a-possibility
#17
C S Chia, B You, E Decullier, D Vaudoyer, G Lorimier, K Abboud, J-M Bereder, C Arvieux, G Boschetti, O Glehen
BACKGROUND: Peritoneal carcinomatosis is an increasingly common finding in gastric carcinoma. Previously, patients were treated as terminal, and median survival was poor. The use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in this context is still highly debatable. OBJECTIVE: The aim of this study was to evaluate the long-term outcomes associated with CRS and HIPEC, and define prognostic factors for cure, if possible. PATIENTS AND METHODS: All patients with gastric carcinomatosis from five French institutions who underwent combined complete CRS and HIPEC and had a minimum follow-up of 5 years were included in this study...
June 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/26698380/peritoneal-carcinomatosis-from-unusual-cancer-origins-is-there-a-role-for-hyperthermic-intraperitoneal-chemotherapy
#18
C Honoré, D Goéré, R Macovei, L Colace, L Benhaim, D Elias
INTRODUCTION: Complete cytoreductive surgery (CCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is the gold standard for curative treatment of peritoneal carcinomatosis (PC) arising from colorectal cancer, peritoneal mesothelioma and peritoneal pseudomyxoma peritonei (PMP). The results of HIPEC remain controversial in PC that originates from ovarian cancer, stomach cancer, neuroendocrine tumors, or sarcoma. HIPEC has also been used, although very rarely, for other malignant carcinomatoses...
April 2016: Journal of Visceral Surgery
https://www.readbyqxmd.com/read/26670720/evolution-and-emerging-future-of-cytoreducxtive-surgery-and-hyperthermic-intraperitoneal-chemoperfusion-in-gastric-cancer-from-treating-the-incurable-to-preventing-recurrence
#19
Karol Polom, Luigi Marano, Giandomenico Roviello, Roberto Petrioli, Riccardo Piagnerelli, Lorenzo de Franco, Daniele Marrelli, Franco Roviello
The number of new gastric cancer (GC) cases is decreasing, and these patients have longer survival thanks to new oncological treatments. In advanced GC a common evolution of this neoplasm is peritoneal metastases (PM). In the past this finding meant no chance for cure. However, today, using high quality operations and HIPEC, we are able to increase the number of patients treated with curative intention. New options in the diagnosis of PM, tumour susceptibility for different drugs, importance of quality of life, usage in ascites treatment, diagnostic tools in image-guided surgery, new targeted therapies and analysis of currently ongoing trials are presented together with today's knowledge of HIPEC efficacy in order to evaluate gastric PM...
2016: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/26542584/laparoscopy-is-safe-and-accurate-to-evaluate-peritoneal-surface-metastasis-prior-to-cytoreductive-surgery
#20
Rebecca A Marmor, Kaitlyn J Kelly, Andrew M Lowy, Joel M Baumgartner
BACKGROUND: Completeness of cytoreduction is a significant predictor of long-term outcome after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Imaging has limited sensitivity to identify peritoneal metastases and therefore predict whether complete cytoreduction is possible. We reviewed our experience using laparoscopy to determine candidates for complete cytoreduction and HIPEC. METHODS: This single-center, retrospective study examined patients from 2007 to 2014 who underwent laparoscopy to determine complete cytoreduction (CC-0/1)/HIPEC candidacy...
May 2016: Annals of Surgical Oncology
keyword
keyword
98794
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"